InvestorsHub Logo
Followers 5
Posts 213
Boards Moderated 0
Alias Born 08/19/2013

Re: biotech2010 post# 2157

Tuesday, 05/10/2016 10:22:24 AM

Tuesday, May 10, 2016 10:22:24 AM

Post# of 3834
"GR-MD-02 in patients with moderate-to-severe plaque psoriasis. We look forward to reporting interim data from this study in the near future. "

I had asked the company about this last year, if there would be a interim report. The response was no.
The trial was designed to dose and than follow the patients for 1 year after.
This new development of a interim report points to a positive response for this trial. I don't think they would say "we look forward to reporting" and than give bad results. If results were not positive they would wait as planned and quietly PR the failure.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News